Literature DB >> 31617731

Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension.

Jason M Elinoff1, Adrien J Mazer1, Rongman Cai1, Mengyun Lu1, Grace Graninger1, Bonnie Harper1, Gabriela A Ferreyra1, Junfeng Sun1, Michael A Solomon1,2, Robert L Danner1.   

Abstract

Inflammatory cell infiltrates are a prominent feature of aberrant vascular remodeling in pulmonary arterial hypertension (PAH), suggesting that immune effector cells contribute to disease progression. Genome-wide blood expression profiling studies have attempted to better define this inflammatory component of PAH pathobiology but have been hampered by small sample sizes, methodological differences, and very little gene-level reproducibility. The current meta-analysis (seven studies; 156 PAH patients/110 healthy controls) was performed to assess the comparability of data across studies and to possibly derive a generalizable transcriptomic signature. Idiopathic (IPAH) compared with disease-associated PAH (APAH) displayed highly similar expression profiles with no differentially expressed genes, even after substantially relaxing selection stringency. In contrast, using a false discovery rate of ≤1% and I2 < 40% (low-to-moderate heterogeneity across studies) both IPAH and APAH differed markedly from healthy controls with the combined PAH cohort yielding 1,269 differentially expressed, unique gene transcripts. Bioinformatic analyses, including gene-set enrichment, which uses all available data independent of gene selection thresholds, identified interferon, mammalian target of rapamycin/p70S6K, stress kinase, and Toll-like receptor signaling as enriched mechanisms within the PAH gene signature. Enriched biological functions and diseases included tumorigenesis, autoimmunity, antiviral response, and cell death consistent with prevailing theories of PAH pathogenesis. Although otherwise indistinguishable, APAH (predominantly PAH due to systemic sclerosis) had a somewhat stronger interferon profile than IPAH. Meta-analysis defined a robust and generalizable transcriptomic signature in the blood of PAH patients that can help inform the identification of biomarkers and therapeutic targets.

Entities:  

Keywords:  blood mononuclear cells; inflammation; interferon; microarray; pulmonary arterial hypertension

Mesh:

Substances:

Year:  2019        PMID: 31617731      PMCID: PMC6985867          DOI: 10.1152/ajplung.00252.2019

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  58 in total

1.  Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

2.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

3.  RNA Sequencing and Analysis.

Authors:  Kimberly R Kukurba; Stephen B Montgomery
Journal:  Cold Spring Harb Protoc       Date:  2015-04-13

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Pulmonary arterial hypertension in patients treated with interferon.

Authors:  Laurent Savale; Caroline Sattler; Sven Günther; David Montani; Marie-Camille Chaumais; Swanny Perrin; Xavier Jaïs; Andrei Seferian; Roland Jovan; Sophie Bulifon; Florence Parent; Gérald Simonneau; Marc Humbert; Olivier Sitbon
Journal:  Eur Respir J       Date:  2014-10-16       Impact factor: 16.671

6.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

7.  EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.

Authors:  Mélanie Eyries; David Montani; Barbara Girerd; Claire Perret; Anne Leroy; Christine Lonjou; Nadjim Chelghoum; Florence Coulet; Damien Bonnet; Peter Dorfmüller; Elie Fadel; Olivier Sitbon; Gérald Simonneau; David-Alexandre Tregouët; Marc Humbert; Florent Soubrier
Journal:  Nat Genet       Date:  2013-12-01       Impact factor: 38.330

8.  GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology.

Authors:  Haiyun Liu; Lei Huang; Jillian Bradley; Kebin Liu; Kankana Bardhan; David Ron; Andrew L Mellor; David H Munn; Tracy L McGaha
Journal:  Mol Cell Biol       Date:  2013-11-18       Impact factor: 4.272

9.  TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes.

Authors:  V Matys; O V Kel-Margoulis; E Fricke; I Liebich; S Land; A Barre-Dirrie; I Reuter; D Chekmenev; M Krull; K Hornischer; N Voss; P Stegmaier; B Lewicki-Potapov; H Saxel; A E Kel; E Wingender
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

10.  Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a.

Authors:  Irene Sarrion; Lara Milian; G Juan; Mercedes Ramon; Idelfonso Furest; Carmen Carda; Julio Cortijo Gimeno; Manuel Mata Roig
Journal:  Oxid Med Cell Longev       Date:  2015-02-25       Impact factor: 6.543

View more
  15 in total

1.  Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome.

Authors:  Christopher J Rhodes; Pablo Otero-Núñez; John Wharton; Emilia M Swietlik; Sokratis Kariotis; Lars Harbaum; Mark J Dunning; Jason M Elinoff; Niamh Errington; A A Roger Thompson; James Iremonger; J Gerry Coghlan; Paul A Corris; Luke S Howard; David G Kiely; Colin Church; Joanna Pepke-Zaba; Mark Toshner; Stephen J Wort; Ankit A Desai; Marc Humbert; William C Nichols; Laura Southgate; David-Alexandre Trégouët; Richard C Trembath; Inga Prokopenko; Stefan Gräf; Nicholas W Morrell; Dennis Wang; Allan Lawrie; Martin R Wilkins
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

2.  Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension.

Authors:  Salina Gairhe; Keytam S Awad; Edward J Dougherty; Gabriela A Ferreyra; Shuibang Wang; Zu-Xi Yu; Kazuyo Takeda; Cumhur Y Demirkale; Parizad Torabi-Parizi; Eric D Austin; Jason M Elinoff; Robert L Danner
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

3.  Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension.

Authors:  Sean Agbor-Enoh; Michael A Solomon; Samuel B Brusca; Jason M Elinoff; Yvette Zou; Moon Kyoo Jang; Hyesik Kong; Cumhur Y Demirkale; Junfeng Sun; Fayaz Seifuddin; Mehdi Pirooznia; Hannah A Valantine; Carl Tanba; Abhishek Chaturvedi; Grace M Graninger; Bonnie Harper; Li-Yuan Chen; Justine Cole; Manreet Kanwar; Raymond L Benza; Ioana R Preston
Journal:  Circulation       Date:  2022-08-25       Impact factor: 39.918

4.  IL-13 alleviates idiopathic pulmonary hypertension by inhibiting the proliferation of pulmonary artery smooth muscle cells and regulating macrophage infiltration.

Authors:  Ruda Wei; Liting Chen; Pengchuan Li; Chaoyang Lin; Qingshi Zeng
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 5.  Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension.

Authors:  Christopher J Rhodes; Andrew J Sweatt; Bradley A Maron
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

6.  Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.

Authors:  Mengyun Lu; Li-Yuan Chen; Salina Gairhe; Adrien J Mazer; Stasia A Anderson; Jasmine N H Nelson; Audrey Noguchi; Mohammad Abdul Hai Siddique; Edward J Dougherty; Yvette Zou; Kathryn A Johnston; Zu-Xi Yu; Honghui Wang; Shuibang Wang; Junfeng Sun; Steven B Solomon; Rebecca R Vanderpool; Michael A Solomon; Robert L Danner; Jason M Elinoff
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-01-19       Impact factor: 5.464

Review 7.  NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review.

Authors:  William M Oldham; Anna R Hemnes; Micheala A Aldred; John Barnard; Evan L Brittain; Stephen Y Chan; Feixiong Cheng; Michael H Cho; Ankit A Desai; Joe G N Garcia; Mark W Geraci; Susan D Ghiassian; Kathryn T Hall; Evelyn M Horn; Mohit Jain; Rachel S Kelly; Jane A Leopold; Sara Lindstrom; Brian D Modena; William C Nichols; Christopher J Rhodes; Wei Sun; Andrew J Sweatt; Rebecca R Vanderpool; Martin R Wilkins; Beth Wilmot; Roham T Zamanian; Joshua P Fessel; Neil R Aggarwal; Joseph Loscalzo; Lei Xiao
Journal:  J Am Coll Cardiol       Date:  2021-04-27       Impact factor: 27.203

8.  Transcriptomic profiles in pulmonary arterial hypertension associate with disease severity and identify novel candidate genes.

Authors:  Casey E Romanoski; Xinshuai Qi; Shreya Sangam; Rebecca R Vanderpool; Robert S Stearman; Austin Conklin; Manuel Gonzalez-Garay; Franz Rischard; Ramon J Ayon; Jian Wang; Tatum Simonson; Aleksandra Babicheva; Yinan Shi; Haiyang Tang; Ayako Makino; Yogendra Kanthi; Mark W Geraci; Joe G N Garcia; Jason X-J Yuan; Ankit A Desai
Journal:  Pulm Circ       Date:  2020-12-07       Impact factor: 3.017

9.  Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension.

Authors:  Anna Hemnes; Alexander M K Rothman; Andrew J Swift; Lawrence S Zisman
Journal:  Pulm Circ       Date:  2020-11-18       Impact factor: 2.886

10.  PHorecasting Heritable Pulmonary Arterial Hypertension: Are We Nearly There Yet?

Authors:  Micheala A Aldred
Journal:  Am J Respir Crit Care Med       Date:  2020-12-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.